Zobrazeno 1 - 10
of 1 183
pro vyhledávání: ''
Autor:
Linlin Yang, Wenrui Duan, Duan-Liang Shyu, Changxian Shen, Amy Webb, Min Xu, Terence M. Williams
Publikováno v:
Mol Cancer Res
Lung squamous cell carcinoma (LUSC) accounts for one of three of non–small cell lung carcinoma (NSCLC) and 30% of LUSC patients present with locally advanced, unresectable/medically inoperable disease, who are commonly treated with definitive chemo
Autor:
J. Qiu, Umesh Bhanot, John T. Poirier, Yingqian Zhan, Elisa de Stanchina, Viola Allaj, Hirokazu Taniguchi, Fathema Uddin, Travis J. Hollmann, Jordana Ray-Kirton, Metamia Ciampricotti, Andrew Chow, Marina Asher, Richard Koche, Álvaro Quintanal-Villalonga, Jacklynn V. Egger, Yuan Hao, Joseph M. Chan, Shweta S Chavan, Charles M. Rudin, Michael H.A. Roehrl, Triparna Sen, Michael Offin, Irina Linkov, Nisargbhai S. Shah, P. Manoj
Publikováno v:
Cancer Res
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent addition of
Autor:
Yinzhong Shang, Linlin Yan, Mingming Wu, Yong Zhu, Tao Zhu, Hui Yuan, Xiao Zhang, Zhengsheng Wu, Qianying Guo, Peter E. Lobie, Xin Ma
Publikováno v:
Cancer Research. 82:391-405
Estrogen receptor alpha (ERα) plays a vital role in the development of normal breast tissue and in breast cancer. By cross-analyzing The Cancer Genome Atlas (TCGA) database, ERα-regulated long noncoding RNA 1 (ERLC1) was identified as a long noncod
Autor:
Becky K. C. Chan, Stephanie Ma, Hoi Yee Chu, Koon Ho Wong, Cindy S.W. Tong, Gigi C. G. Choi, Maggie S. H. Cheung, Tin Lok Wong, Yuanhua Huang, Feng Xu, John H. C. Fong, Alan S.L. Wong, Lakhansing Pardeshi, Man Tong, Kylie Hin-Man Mak
Publikováno v:
Cancer Research. 81:6219-6232
Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinations, we de
Autor:
Jawairia Atif, Kimberly C. Wiegand, T. Michael Underhill, Jacqueline C.Y. Lai, Pauline Johnson, Spencer A. Freeman, Michael R. Gold, Kelly M. McNagny, Marie-Renée Blanchet, Arif A. Arif, Calvin D. Roskelley, Pamela Dean, Yu-Hsuan Huang
Publikováno v:
Molecular Cancer Research. 19:2096-2109
A rate-limiting step for circulating tumor cells to colonize distant organ sites is their ability to locate a microenvironmental niche that supports their survival and growth. This can be achieved by features intrinsic to the tumor cells and/or by th
Publikováno v:
Molecular Cancer Therapeutics. 20:2519-2526
Immune-related pneumonitis is an important toxicity associated with checkpoint inhibitor therapy with anti–PD-1 or anti–PD-L1 antibodies, often necessitating discontinuation of treatment. Development of methods to mitigate checkpoint inhibitor–
Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype
Autor:
Warren Naselsky, Wen Xu, Xi Chen, Suruchi Shrestha, Gautam Adhikary, Jeffrey W. Keillor, Richard L. Eckert
Publikováno v:
Mol Cancer Res
Transglutaminase 2 (TG2) is a key epidermal squamous cell carcinoma cancer cell survival protein. However, how TG2 maintains the aggressive cancer phenotype is not well understood. The present studies show that TG2, which is highly expressed in epide
Autor:
Jinying Shen, Yujie Zhao, Linhai Zhong, Tianhui Hu, Xiong Chen, Xiaolin Xu, Daxuan Wang, Yan-yan Zhan, Xiaoting Hong, Hanwei Cao, Yitong Zhou, Jianben Wu, Ying Lin, Wenqing Zhang, Jihuan Hou
Publikováno v:
Cancer Research. 81:5904-5918
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4
Autor:
Qiang Zhao, Yao Lu, Bingying Luo, Jie Yin, Daowei Wang, Peng Chen, Jie Yan, Long Li, Yangyang Wang, Jian Zheng, Jun Xiao, Zhenyi Xue, Yudong Su
Publikováno v:
Clinical Cancer Research. 28:793-809
Purpose: Anlotinib has achieved good results in clinical trials of a variety of cancers. However, the effects of anlotinib on the tumor microenvironment (TME) and systemic immunity have not been reported. There is an urgent need to identify the under
Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model
Autor:
Jessica Bills, Meili Zhang, Dionne Davis, Monica Manglani, Kunio Nagashima, Stuart Walbridge, Brandon Foster, Dorian B. McGavern, Priya Shankarappa, Amélie Vézina, DreeAnna Morris, Matthew McCord, Hua Song, Jessica Kindrick, William D. Figg, Wei Zhang, Leslie L. Muldoon, Sadhana Jackson, Mark R. Gilbert, Cody J. Peer
Publikováno v:
Mol Cancer Res
The blood–tumor barrier (BTB) limits the entry of effective chemotherapeutic agents into the brain for treatment of malignant tumors like glioblastoma. Poor drug entry across the BTB allows infiltrative glioma stem cells to evade therapy and develo